Rhythm Pharmaceuticals Inc. has presented its long-term growth strategy, highlighting key developments in recent clinical trials and product demand. The company reported strong results from the Phase 3 trial of setmelanotide in acquired hypothalamic obesity and is on track to complete U.S. and EU regulatory submissions in the third quarter of 2025. Additionally, there is solid patient demand growth for IMCIVREE® (setmelanotide) in the first quarter of 2025, with a data readout for the Phase 2 trial of oral bivamelagon in acquired hypothalamic obesity expected in the third quarter of 2025. The company remains well-capitalized, with an expected cash runway extending into 2027. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.